AXGN:NASDAQ
AxoGen, Inc Common Stock
$41.85
arrow_downward
-11.47%(-5.42) 1D
$42.05
arrow_upward
+0.48% (+0.20)bedtimeAfter hours
Closed: Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$45.14
High
$45.50
Low
$41.74
Mkt. cap
2.25B
Avg. vol.
927.61K
Volume
53.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.16
Shares outstanding
53.76M
No. of employees
622
Open
$45.14
High
$45.50
Low
$41.74
Mkt. cap
2.25B
Avg. vol.
927.61K
Volume
53.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.16
Shares outstanding
53.76M
No. of employees
622
News stories
From web sources and news partners
GuruFocus
·
6 hours ago
Axogen Inc (AXGN) Shares Fall 11.5% -- What GF Score of 64 Tells Investors
Benzinga
·
18 hours ago
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Schaeffer's Investment Research
·
20 hours ago
2 Medical-Device Stocks Lighting Up the Options Pits
TipRanks
·
1 day ago
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorMedical device
Websiteaxogeninc.com